Last reviewed 2026-04-20 · How we verify

ARFORMOTEROL TARTRATE

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Pain
• Chest pain
• Back pain
• Diarrhea
• Sinusitis
• Leg cramps
• Dyspnea
• Rash
• Flu syndrome
• Peripheral edema
• Lung disorder
• Headache

Serious adverse events

• Myocardial infarct
• Congestive heart failure
• Arrhythmias
• Angina
• Supraventricular tachycardia
• AV block
• Heart block
• Metabolic acidosis
• Hypokalemia
• Hyperglycemia

Key clinical trials

• A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients (PHASE4)
• Arformoterol/Budesonide for COVID-19 (PHASE2)
• Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
• A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects (PHASE4)
• Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB) (PHASE3)
• Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects (PHASE3)
• Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease (NA)
• Effect of Bronchodilation on Cycle vs Treadmill Exercise Endurance Time in COPD (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ARFORMOTEROL TARTRATE CI brief — competitive landscape report
• ARFORMOTEROL TARTRATE updates RSS · CI watch RSS